Back to top

Analyst Blog

Pluristem Therapeutics Inc. (PSTI - Snapshot Report) recently announced its intention to commence a phase I study that will evaluate the safety and efficacy of the local administration of PLacental eXpanded (PLX) cells to patients suffering from tendon injuries.

The randomized, double blind, placebo-controlled study will be conducted as a part of the company’s plan to expand its presence in the orthopedic and sports medicine markets.

As per the American Academy of Orthopedic Surgeons, about 200,000 Americans require surgery related to repair of the rotator cuff every year.

We note that Pluristem is conducting a phase I/II study evaluating the safety and efficacy of its PLX cells in the treatment of muscle injury. Safety is the primary endpoint of the study while the secondary endpoint is the gluteal muscle function after six months.

A positive outcome from this study will enable Pluristem to further evaluate the potential of PLX cells for this indication along with other non-surgical injuries such as sports injuries.

Pluristem develops placenta-based cell therapies. The cells from placenta are derived using the company’s proprietary PluriX therapy. PluriX cells are a drug delivery platform that releases a number of therapeutic proteins in response to various local and systemic inflammatory and ischemic diseases.

Pluristem’s first product in development, PLX-PAD, is intended to treat peripheral artery disease (PAD).

Pluristem develops and manufactures cell therapy products in collaboration with companies like United Therapeutics (UTHR - Analyst Report) or through research and clinical institutions.

Pluristem carries a Zacks Rank #3 (Hold). Currently, companies like Vertex Pharmaceuticals Incorporated (VRTX - Analyst Report) and Transcept Pharmaceuticals, Inc. look more attractive with a Zacks Rank #1 (Strong Buy).

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
PLANAR SYST… PLNR 4.44 +5.21%
BITAUTO HOL… BITA 81.71 +5.12%
CTPARTNERS… CTP 16.66 +4.26%
CHINA BIOLO… CBPO 47.91 +3.30%
MALLINCKROD… MNK 72.94 +2.85%